Researchers at the University of Waterloo have developed a new system that could significantly speed up the discovery of new drugs and reduce the need for costly and time-consuming laboratory tests.
The new technology called Pattern to Knowledge (P2K) can predict the binding of biosequences in seconds and potentially reduce bottlenecks in drug research.
P2K uses artificial intelligence (AI) to leverage deep knowledge from data instead of relying solely on classical machine learning.
“P2K is a game changer given its ability to reveal subtle protein associations entangled in complex physiochemical environments and powerfully predict interactions based only on sequence data,” said Andrew Wong, professor, Systems Design Engineering, and Founding Director, Centre for Pattern Analysis and Machine Intelligence (CPAMI). “The ability to access this deep knowledge from proven scientific results will shift biological research going forward. P2K has the power to transform how data could be used in the future.”
Although a large amount of biological sequence data has been collected, extracting meaningful and useful knowledge hasn’t been easy. P2K algorithms tackle this challenge by disentangling multiple associations to identify and predict amino acid bindings that govern protein interactions. Since P2K is much faster than existing biosequence analysis software with almost 30 per cent better prediction accuracy, it could significantly speed up the discovery of new drugs. By drawing information from databases in the Cloud, P2K could predict how tumour proteins and potential cancer treatments would interact.
Although still in the early prototype stage, Professor Wong and his team have made the online P2K system available publicly to researchers to start identifying new bio-sequence interactions.
“Putting this AI technology in the hands of biomedical researchers will generate immediate results, which could be used for future scientific discoveries,” said Antonio Sze-To, research associate, Systems Design Engineering, and co-inventor of P2K.
Since it analyzes sequential data, the applicability of P2K isn’t limited to biomedical research. P2K could benefit the financial industry by making useful associations and predictions for smart trading or the cybersecurity sector by predicting the likelihood of a potential cyber attack.
Learn more: New deep knowledge AI system could resolve bottlenecks in drug research
The Latest on: Drug discovery
[google_news title=”” keyword=”drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug discovery
- Global Drug Discovery Informatics Market to Grow by $4.95 Billion During 2022-2027on June 7, 2023 at 2:19 am
The "Global Drug Discovery Informatics Market 2023-2027" report has been added to ResearchAndMarkets.com's offering.The drug discovery informatics market is forecast to grow by USD 4,953.48 mn during ...
- Global partnership to make UQ a major international hub for vaccine discovery and developmenton June 6, 2023 at 8:36 pm
Queensland will become a major international hub for vaccine discovery and development with a global partnership formed in the United States today to help address the world's critical health ...
- On day 3 of ‘One Week One Lab’, IIIM organizes symposium on drug discoveryon June 6, 2023 at 8:12 pm
As part of its ‘One Week One Lab’ (OWOL) Campaign, CSIR-Indian Institute of Integrative Medicine (IIIM) Jammu organized a symposium on drug discovery in hybrid mode, here today. Dr Sunil Kumar Dubey, ...
- ELRIG UK Announces Prof Janet Hemingway and Dr Dave Powell as Keynote Speakers at Drug Discovery 2023on June 6, 2023 at 3:20 am
UK today announced the keynote speakers for Drug Discovery 2023, taking place at the ACC in Liverpool from 18–19 October. Prof Janet Hemingway CBE, FRS, Founding Director of Infection Innovation ...
- Variant Bio Turns Focus from Identifying Genomic Variants to Drug Discoveryon June 6, 2023 at 1:05 am
To date, the company has built a foundation of more than 20 genomic research partnerships across six continents.
- LabDAO Is Charting The Future Of Open-Source AI For Drug Discoveryon June 2, 2023 at 1:47 pm
Read about LabDAO’s latest advance in moving towards such a future with their PLEX command-line tool for open-source drug discovery.
- Revolutionize Preclinical Drug Candidate Discovery with Syntekabioon June 1, 2023 at 5:32 pm
New York, NY --News Direct-- Syntekabio, Inc. Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) drug discovery and development company headquartered in South Korea, announced today the ...
- Parkinson’s Disease Drug Slows ALS Progression in Clinical Trialon June 1, 2023 at 9:17 am
an extremely important result of this study for iPSC drug discovery is the possibility that in vitro drug efficacy evaluation can predict clinical drug efficacy,” the team stated. “In other ...
- Including African data in drug discovery and developmenton May 31, 2023 at 5:01 pm
To address these disparities, we propose greater incorporation of African data into drug discovery and development, as well as the development of African-centric preclinical and clinical models ...
via Bing News